人群乳腺癌筛查中浸润性乳腺癌的过度诊断:短期与长期视角
该研究用微观模拟模型SiMRiSc在法兰德斯地区每两年一次50至69岁筛查项目中估计浸润性乳腺癌过度诊断率。停止筛查后随访5年时总体过度诊断率为每10万筛查妇女20.1例(95%CI 16.9-23.2),起始筛查年龄50岁与68岁分别为12.9与74.2例。结论认为停止筛查后随访≥10年是获得无偏估计的关键,老年女性过度诊断问题更大。
要点
- 每两年一次50至69岁筛查,停止筛查后随访5年总体过度诊断率为每10万筛查妇女20.1例(95%CI 16.9-23.2)。
- 随访5年时起始筛查年龄50岁过度诊断率为12.9(95%CI 4.6-21.1)、68岁为74.2(95%CI 50.9-97.5)/10万筛查妇女。
- 停止筛查后随访≥10年对获得无偏过度诊断估计是关键,老年女性过度诊断问题更大。
核心结论
- 停止筛查后充分随访时间(≥10年)是获得无偏过度诊断估计的关键。
- 浸润性乳腺癌过度诊断在老年女性中比年轻女性问题更大。
研究设计与样本
- 微观模拟模型SiMRiSc针对法兰德斯乳腺癌筛查进行校准与验证,该地区女性50至69岁每两年筛查一次。
- 过度诊断率定义为筛查期间加随访时间内每10万筛查妇女中在无筛查时不会被诊断的浸润性乳腺癌数,随访时间设为5年并在2至15年间变化。
- 过度诊断率计算总体并按年龄分层。
主要发现
- 50至69岁每两年筛查女性停止筛查后随访5年总体过度诊断率为每10万筛查妇女20.1(95%CI 16.9-23.2)。
- 随访5年时起始筛查年龄50岁过度诊断率为每10万筛查妇女12.9(95%CI 4.6-21.1),起始筛查年龄68岁为74.2(95%CI 50.9-97.5)。
- 起始筛查年龄50岁者在随访2年和15年时过度诊断率分别为每10万筛查妇女98.5(95%CI 75.8-121.3)和13.4(95%CI 4.9-21.9)。
- 起始筛查年龄68岁者在随访2年和15年时过度诊断率分别为每10万筛查妇女297.0(95%CI 264.5-329.4)和34.2(95%CI 17.5-50.8)。
关键数值与推荐
- 过度诊断率以每10万筛查妇女中在无筛查时不会被诊断的浸润性乳腺癌数表示,随访时间设为5年并在2至15年间变化。
- 总体过度诊断率按50至69岁每两年筛查女性停止筛查后随访5年计算为每10万筛查妇女20.1(95%CI 16.9-23.2)。
- 起始筛查年龄50岁与68岁在随访5年的过度诊断率分别为每10万筛查妇女12.9(95%CI 4.6-21.1)与74.2(95%CI 50.9-97.5)。
- 起始筛查年龄50岁在随访2年与15年的过度诊断率分别为每10万筛查妇女98.5(95%CI 75.8-121.3)与13.4(95%CI 4.9-21.9)。
- 起始筛查年龄68岁在随访2年与15年的过度诊断率分别为每10万筛查妇女297.0(95%CI 264.5-329.4)与34.2(95%CI 17.5-50.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overdiagnosis of invasive breast cancer (BC) is a contentious issue. OBJECTIVE: The aim of this paper is to estimate the overdiagnosis rate of invasive BC in an organised BC screening program and to evaluate the impact of age and follow-up time. METHODS: The micro-simulation model SiMRiSc was calibrated and validated for BC screening in Flanders, where women are screened biennially from age 50 to 69. Overdiagnosis rate was defined as the number of invasive BC that would not have been diagnosed in the absence of screening per 100,000 screened women during the screening period plus follow-up time (which was set at 5 years and varied from 2 to 15 years). Overdiagnosis rate was calculated overall and stratified by age. RESULTS: The overall overdiagnosis rate for women screened biennially from 50 to 69 was 20.1 (95%CI: 16.9-23.2) per 100,000 women screened at 5-year follow-up from stopping screening. Overdiagnosis at 5-year follow-up time was 12.9 (95%CI: 4.6-21.1) and 74.2 (95%CI: 50.9-97.5) per 100,000 women screened for women who started screening at age 50 and 68, respectively. At 2- and 15-year follow-up time, overdiagnosis rate was 98.5 (95%CI: 75.8-121.3) and 13.4 (95%CI: 4.9-21.9), respectively, for women starting at age 50, and 297.0 (95%CI: 264.5-329.4) and 34.2 (95%CI: 17.5-50.8), respectively, for those starting at age 68. CONCLUSIONS: Sufficient follow-up time (≥10 years) after screening stops is key to obtaining unbiased estimates of overdiagnosis. Overdiagnosis of invasive BC is a larger problem in older compared to younger women.
引用
- Ding L, Poelhekken K, Greuter MJW, et al. Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective. Eur J Cancer. 2022. PMID: 35839596. doi:10.1016/j.ejca.2022.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。